prof. dr. W. (Wim) Timens

Pulmonary pathology

Pathologist
Board of Trustees Dutch National Tissue Portal
Member Council Science and Innovation (Federation of Medical Specialists)
Member Call Advisory Board European Partnership for Personalised Medicine, (EP PerMed)
Member ZonMW programme committee Post-Covid
Chair UMCG Cohort and Biobank Coördination Hub
Chair Committee Digitalisation and Informatics Dutch Society of Pathology
Member FMS Multidisciplinary Scientific commitee Covid19
Member Steering group project BIMS, (Biobank Information Management System), UMCG
Member Steering group project EDFR2.0 (EPD Data For Research), UMCG
Biobank coordinator regional Health-RI node UMCG
Chair Biobank Expert group (SD-CRO), UMCG
Member projectgroup Mutual Recognition Multicenter Biobanks
Board member GRIAC (Groningen Research Institute for Asthma and COPD)
Member Steering group ELSI (Ethical, Legal, Social Implications) Servicedesk
Member Health Sciences committee National Roadmap Large scale Scientific Infrastructure 2023-2024
Vice chair Dutch Working group Thoracic Pathology (NWTP)
Member national Thymomapanel
Member LANS-panel (National Advisory committee Neoplasia of the Esophagus)
Member Editorial Board J. Pathology
Member Editorial Board J. COPD
Co-founder and PI eQTL Lung consortium (collaboration UMC Groningen, UBC, Vancouver, CA, Laval University, Quebec, CA)
Between 2014-2024: from commercial partners he received honoraria ( all fees to UMCG) for expertise/ scientific advisory board/consultancy/ speakers fee: AbbVie, Astellas, AstraZeneca, Bayer, BMS, Biotest, Boehringer Ingelheim, Chiesi, Diaceutics; GSK, Lilly, MSD/Merck, Novartis, Pfizer, Roche/Ventana, Grants (investigator initiated) from Genentech, MSD/Merck, Roche/Ventana